Our Drug Delivery Technology

Our Drug Delivery Technology

Silica monomers and drug substance are emulsified together

Our Drug Delivery Technology

Silica monomers migrate to the oil/water interface in a well – controlled process

Our Drug Delivery Technology

A silica shell is formed

Encapsulation of a drug substance can be made using a variety of techniques, such as solvent evaporation, coacervation, and interfacial polymerization.

Most encapsulations involve organic polymers, such as polymethyl methacrylate, chitosan and cellulose.
The resultant encapsulated drug substance can be an aqueous dispersion of varying payload and volume fraction or a dried powder.  Control over the encapsulation process when organic polymers are used is challenging and is mainly limited to shell thickness.

Other properties of the organic polymer encapsulating material are hard to control.  In contrast, we use proprietary ‘sol-gel’ processes to shape silica on site to form microcapsule shells of almost any size and release rate profile.

Sol-gel is a chemical process whereby amorphous silica, or other metal oxides, are made by forming interconnections among colloidal particles (the “sol”) under increasing viscosity until a rigid silica shell (the “gel”) is formed.
The drug substance that is added during the sol-gel reaction is encapsulated, in a patented technique, by which a core-shell structure is formed.

The drug substance is in the core and the silica is the capsule shell.  At the end of the process, the microcapsules are in the shape of small beads in the range of 1-40µ.

We believe that our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules, creating a protective barrier between the drug substance and the skin, and controls the release rate of the drug substance.

We believe that our delivery system may also enable highly effective novel fixed-dose combinations of two or more otherwise unstable drug substances by creating a silica protective layer around labile drug substances.

Our delivery system only contains inactive ingredients which are listed in the FDA’s inactive ingredients database (IID) and are approved for topical use, potentially simplifying and expediting the regulatory approval process.